Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

The effect of melatonin on endothelial dysfunction in patients after acute coronary syndrome: The MEFACS randomized clinical trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Melatonin: an ancient molecule that makes oxygen metabolically tolerable

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Utility of melatonin to treat surgical stress after major vascular surgery--a safety study.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Triage for selection to colonoscopy?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Severity classification of the quality of recovery-15 score-An observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Jawad Ahmad Zahid
  • Anders Isbrand
  • Jakob Kleif
  • Anne-Marie Voigt Schou-Pedersen
  • Jens Lykkesfeldt
  • Michael Tvilling Madsen
  • Ismail Gögenur
Vis graf over relationer

Endothelial dysfunction (ED) precedes acute coronary syndrome. Oxidative stress results in ED but is reversible. Melatonin is aside from being a circadian hormone also an antioxidant. The aim of this study was to investigate if 25 mg melatonin administered for twelve weeks following acute coronary syndrome (ACS) could improve ED. In this placebo-controlled randomized trial, ED was measured as reactive hyperaemia index (RHI) at baseline, day 14, and 84. The effect was assessed using a generalized estimating equation adjusted for the baseline RHI. As secondary outcome, the concentrations of three biomarkers were measured: L-arginine, asymmetric dimethylarginine, and uric acid. Thirty-one patients were included in the study. The intention-to-treat analysis of the primary outcome had 26 patients due to missing data. The estimated marginal mean difference in RHI at day 14 and 84 between the groups was 0.15 (95% CI: 0.29 - 0.01, p=0.039) in favor of the placebo group. No significant differences in the biomarker concentrations were found. Melatonin treatment after ACS did not improve but may have aggravated ED. The significant difference between groups was in favor of placebo, but this might be due to the effect of missing data or uneven distribution of comorbidities. This article is protected by copyright. All rights reserved.

OriginalsprogEngelsk
TidsskriftJournal of Pineal Research
Sider (fra-til)e12600
ISSN0742-3098
DOI
StatusE-pub ahead of print - 29 jul. 2019

Bibliografisk note

This article is protected by copyright. All rights reserved.

ID: 57670411